Estela Rodriguez: Subcutaneous vs IV Amivantamab + Lazertinib in NSCLC

Estela Rodriguez shared on X/Twitter:

“PALOMA3 Subq (SC) vs IV Amivantamab + Lazertinib, in Refractory EGFR+ NSCLC:

Similar PK outcomes (non-inferiority)
Lower infusion-related reactions (13% vs. 66%) and VTE (9% vs. 14%)
Exploratory OS analysis favors SC (HR 0.62, p=0.02).
SC formulation will make it easier for patients to receive treatment longer.”

Visit the article website.
Source: Estela Rodriguez/X

Estela Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials. Dr. Rodriguez is known to help empower women to take charge of their own healthcare and believes in the power of mentorship.